Scope Fluidics – a biotechnological company listed on NewConnect, owner of innovative medical diagnostics projects – has completed...
READ MORE
Massively Parallel Antimicrobial Susceptibility Testing
facilitating fastest access to precise antibiotic therapies
facilitating fastest access to precise antibiotic therapies
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 881101.
About BacterOMIC
To give doctors access to complete, that is, actionable information on antibiotic susceptibility of bacterial pathogen
To do so within the current workflow and cost structure
of the healthcare system
All of this, in order to:
- expedite access to precision antibiotic therapies
- minimaze risk of complications in treatment of bacterial infections
- minimaze hospitalization time and cost of treatment
Problem
Doctors do not have access to sufficiently broad AST information to order effective, precision antibiotic therapies in a large fraction of hospitalized cases
Data recorded for inpatient stays with bacterial infections in USA: *Health Serv Res. 2019;00:1–11 **Infect Control Hosp Epidemiol. 2019;40:847-854
**AMR in G7 Countries and Beyond, OECD 2015
Clinical need
Antibiotic treatment is only effective when bacterial pathogen
is susceptible to the drug.
Precise treatment of MDR (Multidrug-Resistant) pathogens require precise AST information about as many antibiotics
as possible.
In worst cases, they require information about synergistic action of pairs of antibiotics.
Lack of efficient information
While there are close to a hundred antibiotics availible clinically, testing all of them manually is practically impossible. And most automated systems offering the inexpensive (5-10 USD) tests include only qualitative information about a subset of antibiotics.
Effective testing of pairs of antibiotics is currently not availible.
Solution
BacterOMIC takes antibiotic susceptibility testing (AST) to the next level
by offering quantitative evaluation of all clinically relevant antibiotics
and identificaton of synergistic pairs of antibiotics
The system uses the most trusted microdilution AST, combined with cutting-edge microfluidics to provide unprecedented information density on a single disposable panel. Our technology delivers the first fully comprehensive test – a single panel contains up to 80 clinically relevant antibiotics, or up to 20 checkerboard combinations of antibiotics. For each antibiotic BacterOMIC provides a true MIC value.
Technology
Bacteromic uses the combination of cutting edge microfluidics, detection, data analysis and automation to offer unprecedented information content, throughput, ease of use with virtually no barier to adoption
Microfluidics
- Properietary network of incubation microchambers
- All-in-one cap and sealing technology
- Best-in-class ease of use
Detection & Data Analysis
- Two methods of detecting bacterial growth
- Custom signal and data analysis solutions
- Real-time reporting for MIC and FIC results in the shortest time possible
Fully Automated Testing
- Analysis of up to 60 cartridges
- Random access
- Simplified manual workflow
640 isolated microchambers, each containing
a different antibiotic environment
Analysis of up to 60 panels in parallel,
with random access
Patents pending:
EP 18189593.9
WO 2019/185885 A1
PL 425107
Recorded signal from incubation chamber
and classification of recorded growth curves
Patents pending:
EP 3597768 A1
WO 2020/016200 Α1
Patents pending:
EP 18189586.3
WO 2019/185927 A1
PL 425106
BacterOMIC signal analysis
During incubation, signals from each chamber are classified as positive or negative using PCA analysis
Sample loading
Incubation
Signal detection
Classification of growth curves
Real time reporting
of results
-
Hospital -
Laboratories -
Doctor’s office/ ICU Acute Care
The PCR|ONE system is ideally suited for use in hospital admission wards for systematic and immediate screening of patients. The PCR|ONE system meets key needs: economic efficiency, rapid screening, and rapid adaptation to the changing landscape of the genetic variants of pathogens.
The unique speed and simplicity of use of the PCR|ONE system provides the shortest time to results as well as gold - standard confidence in results. PCR|ONE test panels are executed within 15 minutes with only ~1 minute of hands - on time. A single PCR|ONE system can test up to 30 samples within an 8-hour shift. This high bench-space and cost efficiency means that this system is ideal for integrating into the laboratory environment.
Immediate molecular diagnostics should be available right at the doctor’s office, where patients seek immediate — and informed — help. Many common conditions such as influenza require simultaneous tests against multiple genetic targets. The PCR|ONE platform delivers this capacity in point-of-care format
-
Airport -
Retail Points/Pharmaceries -
Nursing home
Ease of use enables placement of PCR|ONE in a variety of clinically relevant locations, from Point - of - Care and centralized laboratory to airports, drive through stations and any other public places relevant during the spread of pandemics. We can test the high-risk suspect patients selected by a less specific method (e.g.temperature measurement). This reduces costs (by eliminating the isolation of actually negative - i.e. noninfected people), and isolating infected people in an instant.
Non-traditional use scenarios gained momentum, including point - of - care (POC) Dx at pharmacy and retail settings. PCR|ONE fits this trend well thanks to the physical multiplexing that allows offering a wide range of tests and their rapid adaptation, and the ease of use allows it to be located outside the hospital or laboratory.
PCR|ONE allows for non-laboratory workers to perform tests on-site in a plug - and - play mode, so all entrants can be tested to minimise the risk of infection of the most vulnerable elderly people. Moreover, the short TTR offered by PCR|ONE further simplifies the logistics, and resonable cost of a single test increases accessibility.
Advantages
the first automated system that tests all clinically relevant antibiotics in a single test
the first system to test multiple antibiotic combinations to identify synergies effective against AMR
compliance with EUCAST and CLSI guidelines
same workflow and pricing as existing products
BacterOMIC brings value to all shareholders in the AMR challenge:
- Laboratories
- Hospitals
- Patients
Minimum barriers to adoption
Fully compatible with traditional workflow in central and hospital labs
Isolated bacterial strain
Monocultural bacterial suspension
Transfer of suspension into the cartridge
Closing a cap
Placing the cartridges
in a rack
Placing the cartridges rack in automated filling device
Filling up to 10 cartridges at a time
Transfer of filled cartridges into the analyzer
Fully automated analysis of up to 60 samples
Best in class ease of use, compatible with standard microbiology workflows
Competitive pricing
Intuitive software with real-time reporting
News
Bacteromic obtains the first European patent for
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – announced that it has received a conditional decision from the European Patent Office (EPO) to grant a patent on the...
READ MORE
Scope Fluidics launches the BacterOMIC system prevalidation
Bacteromic – a member of the Scope Fluidics S.A. Capital Group – is working according to the assumed schedule and has announced
READ MOREAbout us
Bacteromic has been accelerated
by the Scope Fluidics Group
BacterOMIC has been accelerated in the Scope Fluidics Group (www.scopefluidics.com). The Scope Fluidics Group develops technological projects for medical diagnostics and healthcare. The strategic goal of the Group is to generate profits as a result of sales of independently developed technology projects for global manufacturers of medical devices. The Scope Fluidics Group provides developed projects with financing, access to laboratories and workshops, and crucial administrative facilities and services.
Management board
Prof. Piotr Garstecki
In 2002 he obtained his PhD in Chemistry
from the Institute of Physical Chemistry
of the Polish Academy of Sciences.
Between 2002 and 2005 postdoctoral
fellowship with prof. George Whitesides
at the Department of Chemistry and
Chemical Biology, Harvard University.
Full professor since 2014, coauthor of over
a hundred scientific publications, and over
a hundred patent applications.
Marcin Izydorzak
Chemist, specialist in the physical
chemistry of materials and in photo-
physics. 15 years of hands-on experience
in the management of research and
development teams in pharmaceutical
and technological companies.
10 years of experience in the management
of R&D projects; has managed the
development of a number of marketed
pharmaceutical products.
Szymon Ruta
Graduate of MBA studies at the University of Warsaw. Executive with over 15 years of experience in mergers, acquisitions, investment and restructuring projects. A board member – finance director and a supervisory board member of numerous companies, including companies listed at Warsaw Stock Exchange. As a managing director in an investment fund he was responsible for companies with total value of 125 million EUR.
Contact
Email: contact@bacteromic.com
Address:
Duchnicka 3, building 16, entrance A,
01-796 Warsaw, Poland
Phone: +48 22 376 21 14
KRS: 0000666549
NIP: 5272799008
REGON: 366713370